ANI Pharmaceuticals
ANIP
232 hedge funds and large institutions have $1.29B invested in ANI Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 89 increasing their positions, 76 reducing their positions, and 25 closing their positions.
57% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $874K
17% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 76
12% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 25
1% more funds holding
Funds holding: 230 → 232 (+2)
0.84% less ownership
Funds ownership: 92.01% → 91.17% (-0.84%)
5% less capital invested
Capital invested by funds: $1.35B → $1.29B (-$63.9M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$21M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$13.1M |
| 3 |
FGP
Freestone Grove Partners
San Francisco,
California
|
+$12.4M |
| 4 |
Millennium Management
New York
|
+$12.1M |
| 5 |
Teacher Retirement System of Texas
Austin,
Texas
|
+$9.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$27.7M |
| 2 |
Morgan Stanley
New York
|
-$15.4M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$11.3M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$11.3M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$11.1M |
ANIP Hedge Fund Activity: Q2 2025 in Review
232 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2025, worth a combined $1.29B — down 4.7% from $1.35B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ANIP positions and 25 closed out — a net gain of 3 holders — while 89 added to existing stakes and 76 trimmed.
The largest buyer was Nuveen, adding an estimated $21M. The largest seller was Goldman Sachs, cutting an estimated $27.7M.
- 232 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2025, up from 230 in Q1 2025.
- Funds reported $1.29B of ANI Pharmaceuticals stock for Q2 2025, down 4.7% quarter-over-quarter.
- 28 funds opened new ANI Pharmaceuticals positions in Q2 2025 and 25 closed out, a net change of +3 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2025 was Nuveen, an estimated $21M added.
- The largest ANI Pharmaceuticals seller in Q2 2025 was Goldman Sachs, an estimated $27.7M sold.
Based on aggregated 13F filings for Q2 2025.